As of November 6, 2026, Vanda Pharmaceuticals Inc. is a publicly traded company (Nasdaq: VNDA); its largest reported holder is Millennium, with 7% on Schedule 13G/A of October 9, 2026, then BlackRock (5.9%). The largest insider holding is Polymeropoulos Mihael Hristos, the chief executive and president, with 2,704,496 shares (4.5% of shares outstanding), per Form 4 of March 4, 2026 (Schedule 13G/A, October 9, 2026).
Is this your company?
About to sign with, pay or invest in Vanda Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vanda Pharmaceuticals Inc. a real, registered company?
- Vanda Pharmaceuticals Inc. files with the SEC under CIK 1347178 (its SEC filings).
- Its shares are listed under the ticker VNDA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Washington, District of Columbia, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Vanda Pharmaceuticals Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Charles C. Duncan, Director (Form 8-K filed 2026-04-22). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Vanda Pharmaceuticals Inc.'s owners and officers?
Vanda Pharmaceuticals Inc.: incorporated in Delaware; business address in Washington, District of Columbia; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock Portfolio Management LLC | 5.9% |
| Schedule 13G/A, 2026-10-09 | Millennium Management LLC | 7% |
| Schedule 13G, 2026-08-19 | Millennium Management LLC | 5.6% |
| Schedule 13G, 2026-08-13 | Aqr Capital Management, LLC | 5.82% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 5.1% |
| Schedule 13G/A, 2026-04-29 | Blackrock Portfolio Management LLC | 4.2% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-01-21 | Blackrock Portfolio Management LLC | 5.5% |
| Schedule 13G/A, 2026-01-09 | Millennium Management LLC | 2.8% |
| Schedule 13G, 2025-07-01 | Millennium Management LLC | 5.3% |
Questions about who owns Vanda Pharmaceuticals Inc.
Who owns Vanda Pharmaceuticals Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Vanda Pharmaceuticals Inc.: Millennium Management LLC (7%, Schedule 13G/A, filed 2026-10-09), Blackrock Portfolio Management LLC (5.9%, Schedule 13G, filed 2026-10-27), Aqr Capital Management, LLC (5.82%, Schedule 13G, filed 2026-08-13) and State Street Corporation (5.1%, Schedule 13G, filed 2026-05-12).
Who are the largest shareholders of Vanda Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Vanda Pharmaceuticals Inc. on this page are Millennium Management LLC (7%), Blackrock Portfolio Management LLC (5.9%) and Aqr Capital Management, LLC (5.82%).
When did Millennium Management LLC buy into Vanda Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Millennium Management LLC on this page is the Schedule 13G, filed 2025-07-01, reporting 5.3%; its latest, Schedule 13G/A filed 2026-10-09, reports 7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vanda Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vanda Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vanda Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-22 | Charles C. Duncan | Director | appointed |
Which insiders own Vanda Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 2,704,496 shares (4.5% of shares outstanding) (Form 4, 2026-03-04).
- , the senior vice president and business development: 494,197 shares (0.82% of shares outstanding) (Form 4, 2026-03-04).
- , the chief financial officer and senior vice president: 412,015 shares (0.68% of shares outstanding), 411,380 held directly and 635 indirectly (Form 4, 2026-03-04).
- , the general counsel and senior vice president: 377,450 shares (0.62% of shares outstanding) (Form 4, 2026-03-04).
- , the senior vice president and chief marketing officer: 333,469 shares (0.55% of shares outstanding) (Form 4, 2026-03-04).
Shares outstanding: 60,469,687 as of 2026-10-22, from the company's latest SEC cover page.
How much has Vanda Pharmaceuticals Inc. raised?
No fundraising or offering filing from Vanda Pharmaceuticals Inc. is on file with us.
Keep reading
More on Vanda Pharmaceuticals Inc. and the records around it.
Vanda Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Apr 2026
Companies that share a holder
- BlackRock Portfolio Management LLC also filed stake reports on 118 other companies: AMERISAFE INC (Nov 2026), BlackRock ETF Trust (Nov 2026), iShares J.P. Morgan EM Local Currency Bond ETF (Nov 2026)
- Millennium Management LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vanda-pharmaceuticals